Compare QTRX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTRX | BDTX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.0M | 171.9M |
| IPO Year | 2017 | 2020 |
| Metric | QTRX | BDTX |
|---|---|---|
| Price | $3.87 | $1.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $6.00 | ★ $9.67 |
| AVG Volume (30 Days) | 1.1M | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,632,000.00 | N/A |
| Revenue This Year | $25.49 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 64.52 | N/A |
| 52 Week Low | $2.40 | $1.60 |
| 52 Week High | $8.77 | $4.94 |
| Indicator | QTRX | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 46.63 |
| Support Level | $2.98 | $1.60 |
| Resistance Level | $4.57 | $2.30 |
| Average True Range (ATR) | 0.37 | 0.16 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 51.80 | 47.15 |
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.